Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
申请人:Endres Gregory W.
公开号:US08536185B2
公开(公告)日:2013-09-17
Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).
[EN] MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES<br/>[FR] COMPOSES MULTIHETEROARYLES SERVANT D'INHIBITEURS DE LA H-PGDS, AINSI QUE LEUR UTILISATION DANS LE TRAITEMENT DES MALADIES INDUITES PAR LA PROSTAGLANDINE D2
申请人:CAYMAN CHEM CO
公开号:WO2010033977A2
公开(公告)日:2010-03-25
Multiheteroaryl compounds, their preparation, pharmaceutical compositions comprising these compounds, and their pharmaceutical use in the prevention and treatment of prostaglandin D2 mediated diseases and conditions that may be modulated by the inhibition of hematopoietic prostaglandin D synthase (H-PGDS).